HM1. 24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1. 24 antibody

HM1. 24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1. 24 antibody
Authors Wei Wang, Yasuhiko Nishioka, Shuji Ozaki, Ali Jalili, Shinji Abe, Soji Kakiuchi, Masatoshi Kishuku, Kazuo Minakuchi, Toshio Matsumoto, Saburo Sone
Publication date 2009/6
Journal Cancer Immunology, Immunotherapy
Volume 58
Pages 967-976
Publisher Springer-Verlag
Description HM1.24 antigen (CD317) was originally identified as a cell surface protein that is preferentially overexpressed on multiple myeloma cells. Immunotherapy using anti- HM1.24 antibody has been performed in patients with multiple myeloma as a phase I study. We examined the expression of HM1.24 antigen in lung cancer cells and the possibility of immunotherapy with anti-HM1.24 antibody which can induce antibody- dependent cellular cytotoxicity (ADCC). The expression of HM1.24 antigen in lung cancer cells was examined by flow cytometry as well as immunohistochemistry using anti-HM1.24 antibody. ADCC was evaluated using a 6-h 51Cr release assay. Effects of various cytokines on the expression of HM1.24 and the ADCC were examined. The antitumor activity of anti-HM1.24 antibody in vivo was examined in SCID mice. HM1.24 antigen was detected in 11 of 26 non-small cell lung cancer cell lines…
Total citations Cited by 72
Scholar articles HM1. 24 (CD317) is a novel target against lung cancer for immunotherapy using anti- HM1. 24 antibody
W Wang, Y Nishioka, S Ozaki, A Jalili, S Abe… – Cancer Immunology, Immunotherapy, 2009
Cited by 72 Related articles All 14 versions